Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
ISRCTN16472226 Sutacimig Genetic Diseases, Inborn Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
ISRCTN16472226 clinical trial report covering Sutacimig, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07476794 Temozolomide Glioblastoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07476794 clinical trial report covering Temozolomide, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07477431 Levetiracetam Alzheimer Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07477431 clinical trial report covering Levetiracetam, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600120552 Lenvatinib mesylate Locally Advanced Cholangiocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
ChiCTR2600120552 clinical trial report covering Lenvatinib mesylate, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
JPRN-jRCT2031250820 Givastomig Liver metastases Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
JPRN-jRCT2031250820 clinical trial report covering Givastomig, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07476001 Testosterone Cypionate Metastatic castration-resistant prostate cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07476001 clinical trial report covering Testosterone Cypionate, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07475806 Enfortumab Vedotin-ejfv Muscle Invasive Bladder Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07475806 clinical trial report covering Enfortumab Vedotin-ejfv, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07477366 Nogapendekin alfa inbakicept-pmln Refractory Indolent Non-Hodgkin Lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07477366 clinical trial report covering Nogapendekin alfa inbakicept-pmln, Phase 2, endpoints, sponsor, geography, readout timing and development white
Latest Hotspot
8 min read
NCT07477457 Trametinib dimethyl sulfoxide Neoplasm Metastasis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07477457 clinical trial report covering Trametinib dimethyl sulfoxide, Phase 2, endpoints, sponsor, geography, readout timing and development white spac
Latest Hotspot
8 min read
ChiCTR2600120556 GBI268 Pain, Postoperative Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
ChiCTR2600120556 clinical trial report covering GBI268, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07476677 Darolutamide Localized Prostate Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07476677 clinical trial report covering Darolutamide, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07477795 Secukinumab Takayasu Arteritis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07477795 clinical trial report covering Secukinumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.